Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Elucidating the Molecular Mechanisms of the Novel Anti-Convulsant Retigabine Using Voltage Clamp Fluorimetry and Unnatural Amino Acid Mutagenesis

FY 2013-14

Summary
Epilepsy encompasses a diverse set of neurological conditions characterized by frequent seizures due to abnormal and excessive electrical activity in the brain. Despite the availability of over 20 drugs on the market for the management of epileptic seizures, there is a significant unmet need with over 30% of the target population being refractory to these existing therapies. One of the challenges in developing effective therapies is to identify new mechanisms that contribute to the generation and propagation of seizures, without producing harmful side effects. A principal reason for the unmet need in seizure therapy is the redundancy of existing drugs that act on similar mechanisms or targets. For instance, many anti-convulsants in use today are sodium channel inhibitors that act as ‘brakes’ on excessive electrical firing in the brain. The importance of finding effective drugs that act through novel mechanisms has been highlighted by the efficacy of the new anti-convulsant retigabine in patients suffering from seizures, who did not respond well to conventional anti-epileptic drugs. Clinical trials reported an average of 23-35% reduction in seizure frequency, with over a quarter of the patients treated with retigabine experiencing 50% or greater reductions in seizure frequency. Retigabine is the first anti-convulsant that is able to suppress excessive electrical firings in the brain by activating voltage-gated potassium channels. The molecular target of retigabine is a specific channel type referred to ‘M channels’, and the ability of retigabine to promote opening of these channels is a unique property that has not been explored in detail. As a ‘first-in-class’ drug, it may serve as a platform for refinement and improvement of effectiveness (or minimization of side effects). Therefore, understanding the detailed mechanism of retigabine action will provide insights into rational development of more effective derivatives and possibly, channel openers for other ion channel types. To address this question, I am applying a very unique methodology referred to as Unnatural Amino Acid mutagenesis (UAAm) that allows for much more subtle manipulation of protein structure than can be done by conventional mutagenesis. Using UAAm to modify parts of the protein known to be involved in retigabine binding, we will be able to answer very specific questions related to the chemical interactions that underlie its beneficial effects. We will also use spectroscopic methods to test the effects of retigabine on regions of the channel protein involved in controlling their voltage-dependent response. UBC is one of only a few sites worldwide that has routinely utilized the technique of UAAm to enhance structure and function studies of ion channels. As a front-runner in the application of this technique, UBC provides an excellent environment for me to gain unique experience and expertise with UAAm. The combination of these cutting edge approaches to study pharmacology will deliver exciting findings describing the detailed mechanism of action of an important emerging class of anti-epileptic drugs.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
312033
Name
Kim Robin Y
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidating the Molecular Mechanisms of the Novel Anti-Convulsant Retigabine Using Voltage Clamp Fluorimetry and Unnatural Amino Acid Mutagenesis
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Convulsant; Electrophysiology; Epilepsy; Ion Channels; Mechanisms; Neuroscience; Pharmacology; Treatment; Two Electrode Voltage Clamping; Unnatural Amino Acids
Abstract
Epilepsy encompasses a diverse set of neurological conditions characterized by frequent seizures due to abnormal and excessive electrical activity in the brain. Despite the availability of over 20 drugs on the market for the management of epileptic seizures, there is a significant unmet need with over 30% of the target population being refractory to these existing therapies. One of the challenges in developing effective therapies is to identify new mechanisms that contribute to the generation and propagation of seizures, without producing harmful side effects. A principal reason for the unmet need in seizure therapy is the redundancy of existing drugs that act on similar mechanisms or targets. For instance, many anti-convulsants in use today are sodium channel inhibitors that act as ‘brakes’ on excessive electrical firing in the brain. The importance of finding effective drugs that act through novel mechanisms has been highlighted by the efficacy of the new anti-convulsant retigabine in patients suffering from seizures, who did not respond well to conventional anti-epileptic drugs. Clinical trials reported an average of 23-35% reduction in seizure frequency, with over a quarter of the patients treated with retigabine experiencing 50% or greater reductions in seizure frequency. Retigabine is the first anti-convulsant that is able to suppress excessive electrical firings in the brain by activating voltage-gated potassium channels. The molecular target of retigabine is a specific channel type referred to ‘M channels’, and the ability of retigabine to promote opening of these channels is a unique property that has not been explored in detail. As a ‘first-in-class’ drug, it may serve as a platform for refinement and improvement of effectiveness (or minimization of side effects). Therefore, understanding the detailed mechanism of retigabine action will provide insights into rational development of more effective derivatives and possibly, channel openers for other ion channel types. To address this question, I am applying a very unique methodology referred to as Unnatural Amino Acid mutagenesis (UAAm) that allows for much more subtle manipulation of protein structure than can be done by conventional mutagenesis. Using UAAm to modify parts of the protein known to be involved in retigabine binding, we will be able to answer very specific questions related to the chemical interactions that underlie its beneficial effects. We will also use spectroscopic methods to test the effects of retigabine on regions of the channel protein involved in controlling their voltage-dependent response. UBC is one of only a few sites worldwide that has routinely utilized the technique of UAAm to enhance structure and function studies of ion channels. As a front-runner in the application of this technique, UBC provides an excellent environment for me to gain unique experience and expertise with UAAm. The combination of these cutting edge approaches to study pharmacology will deliver exciting findings describing the detailed mechanism of action of an important emerging class of anti-epileptic drugs.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kim, Robin Y
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~